Investor Relations

Latest News

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and Nasdaq (ticker symbol: PMN). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Toronto, Canada Office


1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2

Cambridge, MA U.S. Office


Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142